Soligenix Stock Price - SNGX

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.03 -1.86% 1.58 1.40 1.66 1.60 1.61 20:00:00
Bid Price Ask Price Spread Spread % News
1.42 1.58 0.16 10.13% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,947 392,432 $ 1.52 $ 597,889 554,180 0.65 - 3.54
Last Trade Time Type Quantity Stock Price Currency
17:37:42 formt 200 $ 1.58 USD

Soligenix Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 37.64M 23.82M $ -8.90M -0.74 - 13.92M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Soligenix News

Loading Messages....

Latest SNGX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SNGX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.963.171.331.571,035,322-0.38-19.39%
1 Month2.963.19991.331.95576,138-1.38-46.62%
3 Months1.413.541.332.35547,9080.1712.06%
6 Months0.93283.540.852.15310,8620.647269.38%
1 Year0.933.540.651.77229,0260.6569.89%
3 Years2.47075.080.652.15221,061-0.8907-36.05%
5 Years1.727.600.44011.94180,165-0.14-8.14%

Soligenix Description

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma whereas the Vaccines/BioDefense business segment includes development programs for RiVax, a ricin toxin vaccine candidate; OrbeShield, a GI acute radiation syndrome therapeutic candidate; and SGX943, a melioidosis therapeutic candidate.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.